PolyPid

Poly Pid

Pharmaceuticals, Santa Clara, California, 95051, United States, 11-50 Employees

polypid.com

  • twitter
  • LinkedIn

phone no Phone Number: 97**********

Who is POLYPID

We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes. Our ...

Read More

map
  • Santa Clara, California, 95051, United States Headquarters: Santa Clara, California, 95051, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • Dikla Akselbrad CEO:   Dikla Akselbrad

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 3841

checked-icon Does something look wrong? Fix it. | View contact records from POLYPID

PolyPid Org Chart and Mapping

Employees

Jacob Harel

Chairman of the Board of Directors

Ori Warshavsky

Chief Operating Officer - Us Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding PolyPid

Answer: PolyPid's headquarters are located at Santa Clara, California, 95051, United States

Answer: PolyPid's phone number is 97**********

Answer: PolyPid's official website is https://polypid.com

Answer: PolyPid's revenue is $10 Million to $25 Million

Answer: PolyPid's SIC: 3841

Answer: PolyPid has 11-50 employees

Answer: PolyPid is in Pharmaceuticals

Answer: PolyPid contact info: Phone number: 97********** Website: https://polypid.com

Answer: We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes. Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications. Our product candidates are designed to deliver medications in the body over days to several months in a controlled manner. This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation and cancer. Our initial infection treatment targets are Surgical Site Infections (SSIs), the second most prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative impact on patients clinical outcomes and also pose a significant healthcare system burden. We strive to reduce overall surgical infection rates, including infections due to antibiotic-resistant bacteria which the FDA defined as being one of the worlds most pressing public health problems. NASDAQ: PYPD

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access